Claims
- 1. A method for decreasing or blocking the deleterious effects of endotoxin in a patient who has or is at risk of having a detrimental exposure to endotoxin, said method comprising administering to said patient a therapeutic amount of a compound of the formula: ##STR21## where R.sup.1 is selected from the group consisting of ##STR22## where each J, K and Q, independently, is straight or branched C1 to C15 alkyl; L is O, NH or CH.sub.2 ; M is O or NH; and G is NH, O, S, SO, or SO.sub.2 ;
- R.sup.2 is straight or branched C5 to C15 alkyl;
- R.sup.3 is selected from the group consisting of ##STR23## where E is N, O, S, SO, or SO.sub.2 ; each A, B and D, independently, is straight or branched C1 to C15 alkyl;
- R.sup.4 is selected from the group consisting of straight or branched C4 to C 20 alkyl, and ##STR24## where each U and V, independently, is straight or branched C2 to C15 alkyl and W is hydrogen or straight or branched C1 to C5 alkyl;
- R.sup.5 is selected from the group consisting of hydrogen, J',--J'--OH, --J'--O--K',--J'--O--K'--OH, and --J'--O--PO(OH).sub.2, where each J' and K', independently, is straight or branched C1 to C5 alkyl;
- R.sup.6 is selected from the group consisting of hydroxy, halogen, C1 to C5 alkoxy and C1 to C5 acyloxy;
- A.sup.1 and A.sup.2, independently, are selected from the group consisting of ##STR25## where Z is straight or branched C1 to C10 alkyl; or pharmaceutically acceptable salts thereof.
- 2. The method of claim 1 where said patient has or is at risk of developing systemic inflammatory response syndrome.
- 3. The method of claim 2 where said patient has a gram-negative infection.
- 4. The method of claim 2 where said patient has had a translocation of endotoxin from the gut into the bloodstream.
- 5. The method of claim 2 where said patient has inhaled or is at risk of inhaling endotoxin.
- 6. The method of claim 5 where said patient has or is at risk of developing adult respiratory distress syndrome.
- 7. The method of claim 2 where said patient is infected with a viral pathogen.
- 8. The method of claim 1 where R.sup.2 is C8 to C15 straight or branched alkyl.
- 9. The method of claim 1 where A.sup.1 and A.sup.2, independently, are OH or --O--PO(OH).sub.2.
- 10. The method of claim 1 where R.sup.5 is C1 to C5 straight or branched alkyl.
- 11. The method of claim 1 where R.sup.1 is selected from the group consisting of ##STR26## where each J, K and Q, independently, is straight or branched C1 to C15 alkyl.
- 12. The method of claim 1 where R.sup.3 is selected from the group consisting of ##STR27## where each A, B and D, independently, is straight or branched C1 to C15 alkyl.
- 13. The method of claim 1 where R.sup.4 is selected from the group consisting of straight or branched C4 to C20 alkyl, and ##STR28## where U is straight or branched C2 to C5 alkyl, V is straight or branched C5 to C12 alkyl, and W is hydrogen or straight or branched C1 to C5 alkyl.
- 14. A method of claim 1 where R.sup.6 is hydroxy.
- 15. The method of claim 1 where each A.sup.1 and A.sup.2, independently, is selected from the group consisting of OH and --O--PO(OH).sub.2 ;
- R.sup.1 is selected from the group consisting of ##STR29## where each J, K and Q, independently, is straight or branched C1 to C15 alkyl;
- R.sup.2 is straight or branched C8 to C15 alkyl;
- R.sup.3 is selected from the group consisting of ##STR30## where each A, B and D, independently, is straight or branched C1 to C15 alkyl;
- R.sup.4 is ##STR31## where U is straight or branched C2 to C5 alkyl, V is straight or branched C5 to C12 alkyl and W is hydrogen or straight or branched C1 to C5 alkyl;
- and R.sup.5 is straight or branched C1 to C5 alkyl; and
- R.sup.6 is hydroxy.
- 16. The method of claim 1 where A.sup.1 and A.sup.2 are --O--PO(OH).sub.2 ;
- R.sup.1 is ##STR32## R.sup.2 is (CH.sub.2).sub.9 CH.sub.3 ; R.sup.3 is ##STR33## R.sup.4 is ##STR34## R.sup.5 is methyl; and R.sup.6 is hydroxy.
- 17. A method of claim 1, wherein said compound is ##STR35##
Parent Case Info
This is a divisional application of co-pending application U.S. Ser. No. 08/461,675 filed Jun. 5, 1995.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5066794 |
Shiba |
Nov 1991 |
|
Non-Patent Literature Citations (2)
Entry |
Abstract of Japanese Patent JO 3135-990-A, Oct. 20, 1989. |
Abstract of Japanese Patent JP 03.135.990, Chem Abstracts 115:1008, 1991. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
461675 |
Jun 1995 |
|